Clinical Trial Update: A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation [Phase 4]

View source ↗

Summary

Phase 4 safety evaluation of drotrecogin alfa activated in patients with sepsis related to hematologic neoplasms and bone marrow transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Neoplasms
• Infection
• Sepsis

Drugs mentioned

• Xigran (drotrecogin alfa (activated))

Snippet

Sponsor: Eli Lilly and Company | Conditions: Sepsis, Hematologic Neoplasms | Phase 4 | Status: COMPLETED